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Introduction. Pap smear has limitations as a screening test for cervical cancer. A marker that
allows the identification of women who are at risk of developing cervical cancer would be useful
for its prevention. A growing number of studies have demonstrated an association between
insulin-like growth factors (IGF) serum levels and increased risk for various cancers.
Objective. To assess whether circulating IGF-I, IGF-II, or IGF binding protein 3 (IGFBP-3) were
associated with cervical cancer and low-grade and high-grade squamous intraepithelial lesions
(LSIL and HSIL).
Materials and methods. Serum levels of IGF-I, IGF-II and IGFBP-3 were measured by ELISA.
Three groups of cases were analyzed: LSIL (n = 37), HSIL (n = 57), and cervical cancer (n = 41).
For each case, two controls, matched by age, were included. Control subjects were women
with normal, HPV-DNA-negative Pap smear.
Results. Significantly lower values of IGF-I (83.9 ng/ml versus 126.6 ng/ml, p < 0.001) and IGF-
I:IGFBP-3 molar ratio (0.094 versus 0.137, p < 0.001) were observed among cancer cases, as
compared to their control group. Women in the highest quartile of IGF-I and IGF-I:IGFBP-3
molar ratio were at an 80% (OR = 0.2, 95% CI [0.06-0.61]) and a 77% (OR = 0.23, 95% CI [0.07-
0.73]) lower risk of cervical cancer, respectively, compared with women in the corresponding
reference category.
Conclusions. These data suggest that low values of IGF-I and IGF-I:IGFBP-3 molar ratio may
be  associated with cervical cancer.
Keywords: insulin-like growth factor I, insulin-like growth factor II, insulin-like growth factor
binding protein 3, cervical neoplasms, cervical dysplasia .
Niveles séricos de los factores de crecimiento similares a la insulina I y II y su proteína 3
de enlace  en mujeres con lesiones escamosas intraepiteliales y cáncer de cuello uterino
Introducción. La citología cervico-uterina como prueba de tamizaje del cáncer cervical tiene
limitaciones. Un marcador que permita identificar mujeres en riesgo de desarrollar este cáncer
sería de utilidad para prevenir el desarrollo de esta enfermedad. Múltiples estudios demuestran
asociación entre los factores de crecimiento similares a la insulina (IGF) y varios tipos de
cáncer.
Objetivos. Evaluar si los niveles circulantes de IGF-I, IGF-II, y la proteína 3 de enlace a IGF
(IGFBP-3) se asocian con cáncer cervical y lesiones escamosas intraepiteliales de bajo y alto
grado (LEIBG y LEIAG).
Materiales y métodos. Los niveles séricos de IGF-I, IGF-II e IGFBP-3 se determinaron por
ELISA. Se analizaron tres grupos de casos: LEIBG (n=37), LEIAG (n=57) y cáncer cervical
(n=41), apareados por edad con controles, con citología normal, negativa para ADN de VPH.
Resultados. Se observaron valores de IGF-I (83,9 ng/ml versus 126,6 ng/ml, p < 0,001) y de la
relación molar IGF-I:IGFBP-3 (0,094 versus 0,137, p < 0,001) menores en los casos de cáncer,
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comparados con sus controles. Las mujeres en el cuartil superior de IGF-I y de la relación
molar IGF-I:IGFBP-3 tuvieron un riesgo de cáncer de cérvix 80% (OR = 0.2, IC 95% [0,06-0,61])
y 77% (OR = 0,23, IC 95% [0,07-0,73]) menor, respectivamente, en comparación con las
mujeres en la categoría de referencia.
Conclusiones. Estos datos sugieren que valores bajos de IGF-I y de la relación molar IGF-
I:IGFBP-3 se asocian con cáncer cervical.
Palabras clave: factor I del crecimiento similar a la insulina, factor II del crecimiento similar a
la insulina, proteína 3 de enlace a factor de crecimiento similar a la insulina, neoplasmas del
cuello uterino, displasia del cuello uterino.
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Cervical cancer is a public health problem in
developing countries (1). In Colombia, it is the most
common cause of cancer mortality among women
(2). Persistent infection with high-risk types of HPV
(HR HPV), mainly types 16 and 18, has been
identified as the main risk factor for the
development of cervical cancer and its precursor
lesions, squamous intraepithelial lesions (SILs)
(3). SILs precede the development of cervical
cancer. SILs have been classified into two groups:
low-grade SIL (LSIL) and high-grade SIL (HSIL)
(4). Although HPV infections are among the most
frequent sexually transmitted diseases, infections
are usually self-limited and revert spontaneously,
with only a small group of women developing
cervical cancer (5). The evolution of infection from
LSIL, to HSIL and cancer depends on several
factors, many of which are still unknown. Pap
smear is the most used screening tool for cervical
cancer and SIL. In spite of its wide use, cytology
has limitations in sensitivity, specificity and
reproducibility (6). HPV detection in cervical
scrapings has been proposed as a complementary
or alternative test to Pap smear (7), but, due to
the high prevalence of HPV infections that do not
progress to cancer, HPV testing has a low
specificity (5). A marker that allows us to identify
those women who are at risk of developing cervical
cancer will be a valuable diagnostic tool.
Insulin-like growth factors (IGF-I and IGF-II) are
peptides that play a pivotal role in promoting cell
proliferation and inhibiting apoptosis in many cell
types (8,9). IGF-I and IGF-II actions are mediated
through their binding to the IGF-I receptor (IGF-
IR) (10). In addition, there are six proteins that
bind the IGFs with high affinity (IGFBPs) and are
the major determinants of its bioavailability.
Among these, IGFBP-3 is the best studied and
the most abundant in serum. IGFBP-3 plays a
role modulating the interaction between IGFs and
IGF-IR and can induce apoptosis and inhibit cell
growth independent of IGF-I (11).
Prospective and retrospective studies have
demonstrated an association between IGF-I, IGF-
II and IGFBP-3 serum levels and increased risk
for various cancers (12-15). It has been shown in
animal models that circulating IGF-I levels may
play a significant role in carcinogenesis (16,17).
Some studies have suggested that  serum levels
of IGF-I, IGF-II or IGFBP-3 may be useful
biomarkers for assessing risk of SIL or cervical
cancer development (18-21).
In the present study we investigated if circulating
levels of IGF-I, IGF-II, and IGFBP-3 are associated




After receiving IRB approval, women were
recruited at five outpatient’s gynecological clinics
in Bogotá (Liga Colombiana de Lucha contra el
Cáncer, Hospital de La Samaritana, Hospital de
La Granja, and Instituto Nacional de Cancerología)
from April 2002 through April 2003. The inclusion
criteria for the study were: women younger than
65 years, not pregnant, no previous history of
hysterectomy or cancer, and not under treatment.
All subjects signed written informed consents and
completed an in-person interview, which elicited
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information on demographic features, reproductive
and sexual history, and tobacco use. Clinical and
pathological information for both the case and the
control groups were obtained by a retrospective
chart review. Blood samples and cervical
scrapings  were obtained; serum was separated
from each blood sample by centrifugation and
stored at -70°C. Case subjects were patients with
confirmed histological diagnostic of SIL or cervical
cancer. Control subjects were women with normal,
HPV-DNA-negative Pap smear. The sample size
was not estimated in this study because there
are no reported values of IGF-I, IGF-II and IGFBP-
3 serum levels in Colombian women and these
levels show important variations and wide
distributions among different populations
worldwide. Three groups of cases were conformed:
LSIL (n = 37), HSIL (n = 57), and cervical cancer
(n = 41). For each case, two controls were
selected. Controls were age-matched because age
is the main determinant of IGF serum levels (22).
IGF-I, IGF-II, and IGFBP-3 levels
Commercially available ELISA kits (DSL, Webster,
TX) were used to determine the serum levels of
IGF-I (DSL-10-5600), IGF-II (DSL-10-2600), and
IGFBP-3 (DSL-10-6600). The mean intra- and
inter-assay variation coefficients for the controls
were, respectively, 4.1% and 8.6% for IGF-I, 9.8%
and 13.8% for IGF-II and 4.2% and 11.9% for
IGFBP-3. ELISA was performed according to the
manufacturer’s instructions. Standards, controls,
and samples were tested in duplicate. The IGF-I,
IGF-II, and IGFBP-3 serum concentrations were
determined from the standard curve by matching
the absorbance readings with the corresponding
IGF-I, IGF-II, and IGFBP-3 concentrations.
HPV analysis
Cervical cells from the transformation zone of the
cervix were collected with a cytobrush; harvested
cells were suspended in a saline solution and
subsequently centrifuged at 3,000 x g, 10 min.
Cellular pellet was suspended in 0.75 ml of Trizol
(Gibco) for DNA extraction. Quality of DNA was
tested by amplifying the ß-globin gene using the
primers PCO3/PCO5, as described by Saiki et al.
(23). HPV detection was performed according to
the techniques described by Roda-Husman et al.
(24). Each sample was tested with a generic
primer-mediated PCR with GP5+/GP6+
consensus primers. PCR-amplified products were
further tested in a non-isotopic single-strand
conformational polymorphism (SSCP) for HPV16
and HPV18, as described by Zehbe et al. (25).
PCR-amplified products, excluding positive ones
for HPV16 or HPV18 were typed by direct DNA
sequencing by using the Termo Sequenase Cy5.5
dye terminator cycle sequencing kit and the SEQ
4x4 automated sequencer (Amersham Pharmacia,
Biotech).
Statistical Analysis
Statistical analysis was conducted using SPSS
for Windows, version 11.5 (SPSS Inc., 2002).
Distributions of age, use of hormonal
contraceptives, parity, smoking status and cancer
stage were described, as means and standard
deviations or percentages. Distributions of IGF-I,
IGF-II, and IGFBP3 serum levels, and IGF-
I:IGFBP-3 molar ratio ([IGF-I x 0.13] / [IGFBP-3 x
0.035]) were described, as means, standard
deviations, medians, and interquartile ranges.
Differences in the distributions of these variables
between cases and controls were tested by using
the McNemar test for categorical variables and
the Wilcoxon signed rank test for continuous
variables. Circulating levels of IGF-I, IGF-II,
IGFBP-3, and IGF-I:IGFBP-3 molar ratio were
categorized into quartiles, according to the
distribution of values in their respective control
groups for analysis by univariate and multivariate
conditional logistic models. Distributions of serum
levels into quartiles were described by numbers
and percentages. Univariate and multivariate
logistic regression models were used to assess
the association between cervical cancer, LSIL,
and HSIL and circulating levels of IGFs. The lowest
quartile of each analyzed variable was taken as
the reference category, and crude and adjusted
odds ratios (ORs) and 95% confidence intervals
(CIs) were calculated for the other three quartile
levels. First, crude OR and 95% CI were calculated
in each one of the three groups (LSIL, HSIL, and
cancer) for each variable of interest (IGF-I, IGF-
II, and IGFBP3 plasma levels and IGF-I:IGFBP-3
molar ratio). Then multivariate models were used
to assess the association between each IGF
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Table 1. Characteristics of LSIL cases and controls and IGF serum levels.
LSIL
Variables Cases Controls P
(n = 37) (n = 74)
Mean age (yr) ± s.d. 30.7 ± 8.9 31.2 ± 8.4
Ever smoked No. (%) 12 (32.43) 21 (28.38) 0.607 a
Ever HC use No. (%) 12 (32.43) 28 (37.84) 0.742 a
Parity 1.74 ± 1.78 1.95 ± 1.61 0.211 b
IGF-I ng/ml
Mean ± s.d. 197.0 ± 147.0 180.7 ± 100.9
Median (IQ range) 176.8 (66.0-290.2) 173.9 (115.3-226.3) 0.414 b
1st quartile  No. (%) 13 (35.14) 18 (24.32)
2nd quartile No. (%) 5 (13.51) 19 (25.68)
3rd quartile  No. (%) 4 (10.81) 19 (25.68) 0.057 a
4th quartile  No. (%) 15 (40.54) 18 (24.32)
IGF-II ng/ml
Mean ± s.d. 646.84 ± 144.06 674.3 ± 208.3
   Median (IQ range) 619.2 (520.5-743.0) 631.7 (516.2-814.2) 0.520 b
1st quartile  No. (%) 8 (21.62) 18 (24.32)
2nd quartile No. (%) 12 (32.43) 19 (25.68)
3rd quartile  No. (%) 12 (32.43) 19 (25.68) 0.517 a
4th quartile  No. (%) 5 (13.51) 18 (24.32)
IGFBP-3 ng/ml
Mean ± s.d. 3513.2 ± 1085.7 3912.9 ± 959.5
Median (IQ range) 3494.9 (2995.5-4141.4) 3884.0 (3149.3-4557.7) 0.020 b
1st quartile  No. (%) 13 (35.14) 18 (24.32)
2nd quartile No. (%) 12 (32.43) 19 (25.68)
3rd quartile  No. (%)  4 (10.81) 19 (25.68) 0.246 a
4th quartile  No. (%) 8 (21.62) 18 (24.32)
Molar Ratio
Mean ± s.d. 0.205 ± 0.135 0.173 ± 0.089
Median (IQ range) 0.203 (0.076-0.302) 0.161 (0.103-0.212)  0.058 b
1st quartile  No. (%) 12 (32.43) 18 (24.32)
2nd quartile No. (%) 3 (8.11) 19 (25.68)
3rd quartile  No. (%) 6 (16.21) 19 (25.68) 0.040 a
    4th quartile  No. (%) 16 (43.24) 18 (24.32)
yr: year; No., n: number; LSIL: low-grade squamous intraepithelial lesion; HC: Hormonal contraceptives; s.d: standard
deviation; IQ: Interquartile; Molar ratio = [(IGF-I x 0.13)/ (IGFBP-3 x 0.035)]; a McNemar test; b Wilcoxon signed rank  test.
marker and LSIL, HSIL, and cancer while adjusting
for variables associated with cervical cancer risk
(use of hormonal contraceptives, smoking status,
and parity). IGF-I and IGF-II were adjusted for
IGFBP-3, and IGFBP-3 was as well for IGF-I and
IGF-II, because IGFBP-3 has an effect on IGF-I
and IGF-II activities. Intra-group differences in IGF
levels in LSIL and HSIL related to HR HPV
presence and intra-group differences in IGF levels
in cervical cancer related to stage of disease (I-II
versus III-IV) were tested by using the Mann-
Whitney test. All p values were two-sided and
considered significant at p < 0.05.
Results
Tables 1, 2 and 3 summarize the distributions of
LSIL, HSIL, and cervical cancer cases and their
respective controls by age, tobacco use,
reproductive factors, and FIGO stage; and the
distributions of IGF-I, IGF-II, and IGFBP-3 levels
and IGF-I:IGFBP-3 molar ratio for each group. We
observed differences in mean age between groups;
in HSIL and cervical cancer, the mean age was
higher than in LSIL, which can be related to the
progression in time from LSIL to HSIL to cervical
cancer. There were no differences in the distribution
of tobacco and hormonal contraceptives use. In
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Table 2. Characteristics of HSIL cases and controls and IGF serum levels.
HSIL
Variables Cases Controls P
(n = 57) (n = 114)
Mean age (yr) ± s.d. 38.6 ± 10.4 38.9 ± 9.6
Ever smoked No. (%) 12 (21.10) 28 (24.56) 0.635 a
Ever HC use No. (%) 23 (40.35) 39 (34.21) 0.464 a
Parity 3.25 ± 2.29 2.39 ± 1.79 0.010 b
IGF-I ng/ml
Mean ± s.d. 154.6 ± 104.3 158.3 ± 93.8
Median (IQ range) 133.5 (62-235.1) 144.8 (79.9-223.8) 0.700 b
1st quartile  No. (%) 18 (31.6) 28 (24.6)
2nd quartile No. (%) 12 (21.1) 29 (25.4)
3rd quartile  No. (%) 12 (21.1) 29 (25.4) 0.717 a
4th quartile  No. (%) 15 (26.3) 28 (24.6)
IGF-II ng/ml
Mean ± s.d. 630.6 ± 191.3 646.5 ± 175.7
Median (IQ range) 581.58 (498.3-712.2) 626.29 (518.1-729.9) 0.207 b
1st quartile  No. (%) 17 (29.8) 28 (24.6)
2nd quartile No. (%) 15 (26.3) 29 (25.4)
3rd quartile  No. (%) 13 (22.8) 29 (25.4) 0.869 a
4th quartile  No. (%) 12 (21.1) 28 (24.6)
IGFBP3 ng/ml
Mean ± s.d. 3793.0 ± 1209.3 3698.4 ± 866
Median (IQ range) 3727.9 (3092.1-4293.2) 3675.4 (3087-4374.7) 0.805 b
1st quartile  No. (%) 13 (22.8) 28 (24.6)
2nd quartile No. (%) 15 (26.3) 29 (25.4)
3rd quartile  No. (%) 16 (28.1) 29 (25.4) 0.976 a
4th quartile  No. (%) 13 (22.8) 28 (24.6)
Molar Ratio
Mean ± s.d. 0.149 ± 0.090 0.162 ± 0.092
Median (IQ range) 0.144 (0.066-0.226) 0.151 (0.085-0.229) 0.428 b
1st quartile  No. (%) 17 (29.8) 28 (24.6)
2nd quartile No. (%) 13 (22.8) 29 (25.4)
3rd quartile  No. (%) 14 (24.6) 29 (25.4) 0.904 a
4th quartile  No. (%) 13 (22.8) 28 (24.6)
yr: year; No., n: number; HSIL: high-grade squamous intraepithelial lesion; HC: Hormonal contraceptives; s.d: standard
deviation; IQ: Interquartile; Molar ratio = [(IGF-I x 0.13)/ (IGFBP-3 x 0.035)]; a McNemar test; b Wilcoxon signed rank  test.
contrast, parity was significantly higher in HSIL
cases and in cervical cancer cases than in their
corresponding controls (p = 0.01 and p < 0.001,
respectively).
A statistically significant lower mean circulating
level of IGFBP-3 was observed among LSIL cases
than among controls (3,513.2 ng/ml vs 3,912.9
ng/ml, p = 0.02). In contrast, the mean values of
IGF-I and IGF-I:IGFBP-3 molar ratio were
significantly lower among cancer cases than
among controls. Mean levels of IGF-I were 83.9
ng/ml and 126.6 ng/ml (p < 0.001), and IGF-
I:IGFBP-3 molar ratios were, respectively, 0.094
and 0.137 (p < 0.001) for cervical cancer cases
and the corresponding controls. We did not find
any significant differences in IGF-I, IGF-II, and
IGFBP-3 levels in LSIL or HSIL according to HR
HPV (Table 4).
Crude and adjusted estimates of the association
(OR and 95% CI) between IGF markers and
cervical cancer and precancerous lesions (LSIL
and HSIL) are presented in Table 5.
In LSIL and HSIL groups we did not find any
statistically significant association with serum
levels analyzed in the univariate or multivariate
logistic regression analysis. In the univariate
263
Biomédica 2006;26:258-68 IGFs AND IGFBP-3 IN SIL AND CERVICAL CANCER
Table 3. Characteristics of cervical cancer cases and controls and IGF serum levels.
Cervical cancer
Cases (n= 41) Controls (n=78) P
Mean age (yr) ± s.d. 43.2 ± 8.3 43 ± 8
Ever smoked, No. (%) 9 (22 %) 23 (29.5%) 0.405 a
Ever use of HC,  No. (%) 9 (22 %) 27 (34.6 %) 0.188 a
Parity 4.46 ± 2.44 2.92 ±1.85 <0.001 b
FIGO stage No. (%)
    I 8 (19.5 %)
    II 11 (26.8 %)
    III 18 (43.9 %)
    IV 2 (4.9 %)
    Unknown 2 (4.9 %)
IGF-I ng/ml
Mean ± s.d. 83.9 ± 77.3 126.6 ± 76.6
Median (IQ range) 51.9 (26.6-124.9) 107.7 (68.7-179) <0.001 b
1st quartile  No. (%) 26 (63.41) 19 (24.36)
 2nd quartile No. (%) 3 (7.32) 20 (25.64) <0.001 a
 3rd quartile  No. (%) 7 (17.07) 20 (25.64)
4th quartile  No. (%) 5 (12.20) 19 (24.36)
IGF-II ng/ml
    Mean ± s.d. 594.3 ± 137.3` 638.3 ± 162
    Median (IQ range) 602 (476.2-703.9) 610 (518.4-707.4) 0.194 b
1st quartile  No. (%) 11 (26.83) 19 (24.36)
2nd quartile No. (%) 10 (24.39) 20 (25.64) 0.983 a
3rd quartile  No. (%) 11 (26.83) 20 (25.64)
4th quartile  No. (%) 9 (21.95) 19 (24.36)
IGFBP-3 ng/ml
    Mean ± s.d. 3284 ± 840.6 3567.6 ± 831
    Median (IQ range) 3147.8 (2546.3-3955.9) 3519.2 (2944.9-4105.7) 0.066 b
1st quartile  No. (%) 15 (36.59) 19 (24.36)
2nd quartile No. (%) 11 (26.83) 20 (25.64) 0.395 a
3rd quartile  No. (%) 6 (14.63) 20 (25.64)
    4th quartile  No. (%) 9 (21.95) 19 (24.36)
Molar ratio
    Mean ± s.d. 0.094 ± 0.082 0.137 ± 0.085
    Median (IQ range) 0.065 (0.032-0.114) 0.111 (0.075-0.208) <0.001 b
1st quartile  No. (%) 22 (53.66) 19 (24.36)
2nd quartile No. (%) 7 (17.07) 20 (25.64)
3rd quartile  No. (%) 7 (17.07) 20 (25.64) 0.015 a
    4th quartile  No. (%) 5 (12.20) 19 (24.36)
yr: year; No., n: number; HC: Hormonal contraceptives; s.d: standard deviation; IQ: Interquartile ; FIGO: Federation
Internationale de Gynecologie et d’Obstetrique. Molar ratio = (IGF-I x 0.13) / (IGFBP-3 x 0.035); a McNemar test; b Wilcoxon
signed rank  test.
logistic regression analysis IGF-I levels and IGF-
I:IGFBP-3 molar ratio were found to be inversely
associated with cervical cancer. Women in the
highest quartile of IGF-I and IGF-I:IGFBP-3 molar
ratio were at 80% (OR = 0.2) and 77% (OR = 0.23)
lower risk of cervical cancer, respectively, as
compared with women in the reference category.
After adjusting for variables associated with
cervical cancer risk and with IGFBP-3, this inverse
association remained statistically significant
only for women in the second and third quartiles
of IGF-I (OR = 0.12, 95% IC [0.03-0.51] and OR =
0.27, 95% IC [0.09-0.83], respectively). On the
other hand, after adjusting for variables
associated with cervical cancer risk, the inverse
association between IGF-I:IGFBP-3 molar ratio
and risk of cervical cancer remained statistically
significant for women in the third and fourth
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Table 4. Intragroup comparison of IGF-I, IGF-II, IGFBP-3 and IGF-I:IGFBP-3 molar ratio by high-risk HPV presence or
absence in LSIL and HSIL.
LSIL P* HSIL ** P*
HR HPV (-) HR HPV (+) HR HPV (-) HR HPV (+)
n = 24 n = 13 n = 25 n = 28
IGF-I (ng/ml)
  Mean ± s.d. 167.5 ± 111.9 251.5 ± 189.5 156.8 ± 102.1 139.1 ± 106.6
  Median 158.0 278.84 0.306 131.7 110.7 0.454
  Interquartile range 58.5 - 271.8 71.5 - 388.5 95.5 - 225.5 51.2 - 223.7
IGF-II (ng/ml)
  Mean ± s.d. 674.6 ± 152.6 595.6 ± 115.2 665.2 ± 202.8 591.4 ± 157.6
  Median 674.6 619.2 0.212 647.0 536.2 0.128
  Interquartile range 572.0 - 799.5 480.5 - 671.4 537.2 - 725.2 480.3 - 693.3
IGFBP-3 (ng/ml)
  Mean ± s.d. 3482.3 ± 1007.4 3570.2 ± 1259.2 3972.7 ± 1190.9 3622.6 ± 1262.0
  Median 3483.73 3703.83 0.695 3910.5 3440.3 0.193
  Interquartile range 3025.0 - 3916.1 2457.0 - 4672.1 3190.5 - 4403.4 2846.9 - 4035.6
Molar ratio
  Mean ± s.d. 0.181 ± 0.110 0.251 ± 0.167 0.145 ± 0.082 0.137 ± 0.090
  Median 0.182 0.205 0.276 0.134 0.123 0.735
  Interquartile range 0.075 - 0.292 0.109 - 0.393 0.084 - 0.226 0.058 - 0.201
LSIL: low-grade squamous intraepithelial lesion; HSIL: high-grade squamous intraepithelial lesion. HR HPV: high-risk human
papillomavirus. *: Mann-Whitney test. **: Excluding 4 cases positives for HPV of undetermined type.
quartiles (OR = 0.32, 95% IC [0.1-0.98] and OR
= 0.26, 95% IC [0.08-0.89], respectively). For IGF-
II and IGFBP-3 serum levels in cervical cancer
the differences between cases and controls were
not statistically significant (Table 5).
In order to investigate whether the observed
inverse association between IGF-I and cervical
cancer risk could be related to alterations in
catabolism and nutrition associated to advanced
stages of cancer, we compared serum levels of
IGF-I, IGF-II, and IGFBP-3 and IGF-I:IGFBP-3
molar ratio between stages I-II vs III-IV. We did
not find any significant differences (Table 6).
Discussion
Many studies have suggested that high circulating
IGF-I levels are associated with increased risk of
prostate, premenopausal breast, and colon cancer
(26); however, an inverse association has also
been reported for gastric (27), endometrial (28,29),
liver (30), and lung cancer (31). In this study we
found an inverse association between cervical
cancer risk and IGF-I circulating levels. In
concordance with this result, IGF-I:IGFBP-3 molar
ratio was also inversely associated with cervical
carcinoma. These inverse associations were also
observed in HSIL but did not reach statistical
significance, maybe due to small sample size.
Since IGF-I circulating levels can be affected by
the malignant disease itself, the observed lower
levels of IGF-I in cancer might be more a
consequence of the malignant disease than an
associated risk factor.
Over 75% of IGF-I in the circulation is produced
in the liver. The main physiological stimuli for
hepatic IGF-I synthesis are growth hormone (32)
and nutrition (33). It is plausible that the reduced
circulating IGF-I levels in cancer patients may be
a consequence of alterations in catabolism and
nutrition, conditions commonly present in
advanced stages of this disease. However, we
did not find significant differences in IGF levels
according to FIGO stage (I-II versus III-IV).
In this case-control study we cannot establish
whether this inverse association is a risk factor or
a marker for disease. To solve this question we
would need a prospective study, like the reported
ones in other cancers like prostate (34), breast
(12) and lung (15) cancer. However this kind of
study is difficult to carry out for cervical cancer,
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Table 5. Odds ratio and 95% confidence intervals for LSIL, HSIL and cervical cancer according to serum levels of IGF-I.
IGF-II. IGFBP3 and IGF-I:IGFBP3 molar ratio.
OR (95% IC) associated with quartile
Group Variable 1 2 3 4
LSIL IGF-I
Unadjusted 1.00 0.37 (0.11-1.23) 0.30 (0.08-1.07) 1.15 (0.43-3.08)
Adjusteda 1.00 0.40 (0.11-1.43) 0.40 (0.10-1.60) 3.32 (0.92-12.09)
IGF-II
Unadjusted 1.001 1.42 (0.47-4.25) 1.42 (0.47-4.25) 0.63 (0.17-2.28)
Adjusteda 1.00 1.70 (0.52-5.60) 1.91 (0.58-6.29) 0.83 (0.21-3.20)
IGFBP3
Unadjusted 1.00 0.88 (0.32-2.40) 0.30 (0.08-1.07) 0.62 (0.21-1.84)
Adjustedb 1.00 0.72 (0.25-2.08) 0.23 (0.06-0.90) 0.49 (0.14-1.70)
Molar ratio
Unadjusted 1.00 0.24 (0.06-0.99) 0.48 (0.15-1.53) 1.33 (0.50-3.57)
Adjustedc 1.00 0.20 (0.05-0.89) 0.62 (0.18-2.10) 1.87 (0.63-5.51)
HSIL IGF-I
Unadjusted 1.00 0.65 (0.26-1.58) 0.64 (0.26-1.58) 0.83 (0.35-1.97)
Adjusteda 1.00 0.56 (0.22-1.43) 0.67 (0.26-1.71) 0.85 (0.33-2.22)
IGF-II
Unadjusted 1.00 0.85 (0.36-2.02) 0.74 (0.31-1.80) 0.71 (0.29-1.75)
Adjusteda 1.00 0.85 (0.36-2.02) 0.74 (0.28-1.94) 0.63 (0.23-1.72)
IGFBP3
Unadjusted 1.00 1.11 (0.45-2.75) 1.19 (0.48-2.90) 1.00 (0.40-2.53)
Adjustedb 1.00 1.58 (0.60-4.16) 1.45 (0.56-3.80)  1.30 (0.45-3.78)
Molar ratio
Unadjusted 1.00 0.74 (0.31-1.80) 0.80 (0.33-1.91) 0.76 (0.31-1.87)
Adjustedc 1.00 0.66 (0.26-1.67) 0.92 (0.37-2.27) 0.84 (0.34-2.12)
Cancer IGF-I
Unadjusted 1.00 0.11 (0.03-0.43) 0.26 (0.09-0.73) 0.20 (0.06-0.61)
Adjusteda 1.00 0.12 (0.03-0.51) 0.27 (0.09-0.83) 0.30 (0.08-1.05)
IGF-II
Unadjusted 1.00 0.86 (0.30-2.50) 0.95 (0.33-2.70) 0.82 (0.28-2.42)
Adjusteda 1.00 1.06 (0.32-3.48) 1.32 (0.38-4.64) 1.38 (0.40-4.80)
IGFBP3
Unadjusted 1.00 0.70 (0.26-1.89) 0.38 (0.12-1.19) 0.60 (0.21-1.70)
Adjustedb 1.00 0.96 (0.30-3.10) 0.28 (0.07-1.08) 1.52 (0.43-5.40)
Molar ratio
Unadjusted 1.00 0.30 (0.11-0.87) 0.30 (0.11-0.87) 0.23 (0.07-0.73)
Adjustedc 1.00 0.38 (0.12-1.15) 0.32 (0.10-0.98) 0.26 (0.08-0.89)
LSIL: low-grade squamous intraepithelial lesion; HSIL: high-grade squamous intraepithelial lesion. OR: Odds ratio; 95% CI:
95% confidence intervals; Molar ratio = (IGF-I x 0.13) / (IGFBP-3 x 0.035). a Adjusted by smoking. hormonal contraceptives
use, parity and IGFBP3. b Adjusted by smoking, hormonal contraceptives use, parity and IGF-I e IGF-II. c Adjusted by
smoking, hormonal contraceptives use and parity.
because Pap smears detect preneoplastic lesions,
which ethically forces intervention.
There is one previous report about circulating IGF-
I level in cervical cancer. Ayabe et al. (35), in a
small study of 11 cervical cancer patients and 27
controls, found not significant association between
serum levels of IGF-I and cervical cancer risk.
The difference between their results and ours can
be mainly related to sample size.
We did not find significant association between
precancerous lesions (LSIL and HSIL) and IGF-I
serum levels. Conversely, Wu et al. (20), in a study
of 267 SIL (HSIL and LSIL) cases and 238
controls, reported an association between elevated
serum levels of IGF-I and risk of SIL. This
discrepancy cannot be explained by differences
in the analytical methods, because the same
commercially available assay systems and a
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Table 6. Levels of IGF-I, IGF-II, IGFBP-3 and IGF-I:IGFBP-
3 molar ratio by cancer stage.
Cervical cancer stage*
Stage I-II Stage III-IV P**
(n = 19) (n = 20)
IGF-I ng/ml
 Mean ± s.d. 94.6 ± 82.2 68.6 ± 63.5
 Median 53.6 51.6 0.496
 Interquartile range 27.2-145.1 26.1-79.0
IGF-II ng/ml
 Mean ± s.d. 620.5 ± 136.3 578.0 ± 134.6
 Median 657 571.2 0.258
 Interquartile range 525.3-727.4 469.9-678.7
IGFBP3 ng/ml
 Mean ± s.d. 3369.8 ± 822.6 3251.8 ± 893.0
 Median 3169.9 3032.5 0.588
 Interquartile range 2709.7-4131.9 2524.3-3986.2
Molar ratio
Mean ± s.d. 0.103 ± 0.088 0.079 ± 0.063
 Median 0.07 0.07 0.380
Interquartile range 0.04-0.14 0.03-0.10
*: Excluding 2 cases without data for disease stage.
**: Mann-Whitney test.
similar statistical approach were used in both
studies, and other factors inherent to the sample,
as ethnicity, lifestyle, and diet can affect the result.
For IGF-II and IGFBP-3 serum levels, we did not
find any significant differences in SIL or cancer.
Mathur et al. (18,19,21) report significantly
increased IGF-II and decreased IGFBP-3 serum
levels in women with SIL and cervical cancer. In
this study we used the same commercial assays,
but our statistical approach was quite different and
the small sample subdivided into many different
groups used by Mathur et al. can explain these
discrepancies.  In contrast, Wu et al. found higher
serum levels of IGFBP-3 in SIL cases than in
controls (20). In other cancer types, as breast,
prostate, colon and lung, that have been studied
in greater extent in relation to IGF serum levels,
there are also contradictory results (26). The
complexity of the IGF system and its regulation
makes it difficult to perform direct comparisons
of results, and this hinders the use of serum levels
of IGF-I, IGF-II and IGFBP-3 as biomarkers in
cervical cancer.
It has been well established that HPVs are involved
in the genesis of cervical cancer. Our findings in
intra-group comparisons between presence and
absence of HPV and serum levels of IGF-I, IGF-
II, and IGFBP-3 do not support an association
between HPV infection and IGFs.
In summary, our findings suggest an association
between lower serum levels of IGF-I and a lower
IGF-I:IGFBP-3 molar ratio and cervical cancer.
The case-control design of the study did not allow
us to determine whether lower IGF-I levels are
cause (risk) or consequence (tumor marker) of the
malignant disease.
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